Skip to content

Trial on Probiotics in Prevention of repeated Urinary Tract Infection in Adult Women

Randomised, Double-Blind, Placebo- Controlled Trial Evaluating Safety and Efficacy of add-on Probiotic in Prevention of Recurrent Urinary Tract Infection in Adult Women

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018434
Enrollment
82
Registered
2019-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N328- Other specified disorders of bladder

Interventions

Intervention1: Cap Provinorm: 1. Composition: Cap Provinorm is as follows: i. Lactobacillus acidophilus UBLA-34: 2 billion ii. Lactobacillus rhamnosus UBLR-58: 2 billion iii. Lactobacill

Sponsors

Unique Biotech Linited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i.Women of 18-50 years of age who have not attained menopause ii.Women with an active episode of recurrent UTI iii.Recurrent UTI defined as: a)More than 2 symptomatic, culture-proven UTI over past 6 months OR b)More than 3 symptomatic, culture-proven UTI over past 12 months iv.Willing to give informed consent for the study

Exclusion criteria

Exclusion criteria: i.Polycystic disease, interstitial cystitis, previous urological surgery, stones, or anatomical abnormalities of the urinary tract ii.Pregnant or breastfeeding or planning a pregnancy in the next 6 months iii.Known allergy or intolerance to any of the study products iv.A history of renal stones and/or renal transplantation v.Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes vi.Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement vii.Intermittent or indwelling catheterization

Design outcomes

Primary

MeasureTime frame
I. PRIMARY OBJECTIVE Mean number of confirmed UTIs (either clinical or bacteriological or both) during 24 weeks from start of intervention, as compared to placebo. Timepoint: 0 week Screening eligibility and enrollment followed by evaluations at 4. 8 12 16, 20 and 24 weeks (Last visit)

Secondary

MeasureTime frame
i. To determine time from randomization to first clinical UTI. ii.To report and compare any adverse drug reactions observed in the probiotic versus placebo groups. Timepoint: 0 week Screening eligibility and enrollment followed by evaluations at 4. 8 12 16, 20 and 24 weeks (Last visit)

Countries

India

Contacts

Public ContactDebasish Hota

AIIMS, Bhubaneswar

debhota@gmail.com06742476011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026